BNT 112 - BioNTech
Alternative Names: BNT-112 - BioNTech; W pro1; W_pro1; WP1 cancer vaccine - BioNTechLatest Information Update: 27 Mar 2024
At a glance
- Originator BioNTech
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 23 Jan 2024 BioNTech terminates a phase I/II clinical trials in Prostate cancer (Combination therapy, Newly diagnosed, Metastatic disease) in United Kingdom, Germany, Hungary and USA (IV), due to sponsor decision (NCT04382898)
- 23 Jan 2024 BioNTech terminates a phase I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA, United Kingdom, Hungary, and Germany (IV), due to sponsor decision (NCT04382898)
- 09 Nov 2021 Efficacy and safety data from a phase I/II trial in Prostate cancer released by BioNTech